Vessey Rupert 4

What Happened

• Rupert Vessey, a director of Generate Biomedicines (GENB), received a derivative equity award on Feb 26, 2026 covering 29,561 shares. The Form 4 reports $0.00 consideration for the acquisition and classifies the transaction as an award/grant (code A). A footnote states the shares underlying this option will vest in full on February 19, 2027, subject to his continued service.

Key Details

• Transaction date: 2026-02-26; Form 4 filed: 2026-03-02 (filed late vs. the standard two-business-day reporting window).
• Shares/units granted: 29,561 (derivative award / option per filing footnote).
• Reported consideration: $0.00 on the Form 4 excerpt provided (see full filing for exercise price and full award terms).
• Vesting: full vesting on 2027-02-19, contingent on continued service.
• Shares owned after the transaction: not specified in the provided excerpt.
• Transaction code: A = Award/Grant. Footnote indicates this is an option-type award.

Context

• This was an equity award (not an open-market purchase or sale). Awards to directors are common as part of compensation and do not necessarily signal insider buying or selling intent.
• Because the award vests later, these shares are not immediately exercisable/owned; they become meaningful only if/when vesting and any exercise conditions are met.
• The filing was submitted after the typical two-business-day window (noted above); late filings can affect timeliness of public disclosure but do not by themselves indicate anything about the underlying business.